Chain of non-invasive Cosmetic & Beauty Treatment Clinics (Investment Opportunity) – (Ref. 1183)
London based chain of four clinics offering non-invasive cosmetic and beauty treatments. The Company provides high quality treatments using well qualified staff and modern equipment but at a highly competitive price compared to many existing clinics. Outlets are located near tube and mainline stations with large catchment areas to maximise customer numbers. Started in 2011, the business has been very successful and currently generates a turnover of £600k and generates a pre-tax profit of £110k.
The company is now seeking an investor who, in return for a realistic amount of equity and a high potential ROI, can provide initially £150,000, with the possibility of additional injections of capital, to fund the company’s growth ambitions over the next four years.
The owners are entrepreneurial and ambitious for growth, having spotted a gap in the market for a “cost leadership” chain of cosmetic and beauty clinics. The addressable market in the UK is set to grow to £3.6 billion by 2015, and the company plans to open its own clinics in London and franchises across the rest of the UK and overseas.
Mintel forecasts the market to grow to £3.6 billion by 2015. Today, the annual number of cosmetic procedures in Britain stands at 1.3 million – up 30% over the past two years alone. The market for non –invasive procedures is populated by small clinics that are relatively expensive. The company is seeking to build a strong brand presence and offer excellent quality at affordable prices and secure a profitable share of the market in London with their own clinics, and across the UK and internationally via a franchise model.
In a large but fragmented market Aesthetics of London plan to expand their chain to 15 clinics in London by end 2014/early 2015 and then support these with high profile consumer advertising across the capital to drive regular volume business. Outside of London the plan is to create a network of UK and international clinics via franchise model.
The company is looking to float on AIM or another suitable public market by 2017/2018
Confidentiality Agreement - Chain of non-invasive Cosmetic & Beauty Treatment Clinics (Investment Opportunity) – (Ref. 1183) - Ref 1183
We understand that you wish to investigate the business of the above business (the "Company") in consideration of whether to invest in or acquire the Company (the "Permitted Purpose") and that you, your directors and employees, other potential syndicate members or other providers of finance and your financial and professional advisers in relation to the Permitted Purpose, (together referred to as the "Disclosees"), will need access to certain information relating to the Company (the "Confidential Information").
1. In consideration of our agreeing to supply, and so supplying, the Confidential Information to you and agreeing to enter into discussions with you, you hereby represent that you are a person who falls within Article 19 (disregarding paragraph (6) of that Article) or Article 49 (disregarding paragraph 2(e) of that Article) of the Financial Services and Markets Act 2000 (Financial Promotion) Order and undertake and agree as follows:
(a) to hold the Confidential Information in confidence and not to disclose or permit it to be made available to any person, firm or company (except to other Disclosees) without our prior written consent;
(b) only to use the Confidential Information for the Permitted Purpose;
(c) to ensure that each person to whom disclosure of Confidential Information is made by you is fully aware in advance of your obligations under this letter and that, in the case of other potential syndicate members, each such person gives an undertaking in respect of the Confidential Information, in the terms of this letter;
(d) upon written demand from us either to return the Confidential Information and any copies of it or to confirm to us in writing that, save as required by law or regulation, it has been destroyed. You shall not be required to return reports, notes or other material prepared by you or other Disclosees or on your or their behalf which incorporate Confidential Information (Secondary Information) provided that the Secondary Information is kept confidential;
(e) to keep confidential and not reveal to any person, firm or company (other than Disclosees) the fact of your investigations into the Company or that discussions or negotiations are taking place or have taken place between us in connection with the proposed transaction or that potential investors/acquirers are being sought for the Company;
(f) that no person gives any warranty or makes any representation as to the accuracy or otherwise of the Confidential Information, save as may subsequently be agreed.
This paragraph 1 does not exclude liability for, or any remedy in respect of, fraudulent misrepresentation.
2. Nothing in paragraph 1(a) to (f) of this letter shall apply to any information or Confidential Information:
(a) which at the time of its disclosure is in the public domain;
(b) which after disclosure comes into the public domain for any reason except your failure, or failure on the part of any Disclosee, to comply with the terms of this letter;
(c) which is disclosed by us or the Company, its directors, employees or advisers on a non-confidential basis;
(d) which was lawfully in your possession prior to such disclosure;
(e) which is subsequently received by you from a third party without obligations of confidentiality (and, for the avoidance of doubt, you shall not be required to enquire whether there is a duty of confidentiality); or
(f) which you or a Disclosee are required to disclose, retain or maintain by law or any regulatory or government authority.
3. In consideration of the representation and undertakings given by you in this letter, we undertake and agree:
(a) to disclose Confidential Information to you;
(b) to keep confidential and not to reveal to any person, firm or company (other than persons within our group who need to know, our bankers and professional advisers) the fact of your investigation into the Company or that discussions or negotiations are taking place or have taken place between us; and
(c) confirm that any personal information contained or referred to in any of the Confidential Information, has been obtained, maintained and handled and all relevant licences, authorities and consents have been obtained in accordance with all applicable data protection laws, rules and regulations.
4. No term, condition or provision of this letter shall be enforceable under the Contracts (Right of Third Parties) Act 1999 by a person who is not a party to it.
5. English law and obligations:
(a) This letter shall be governed by and construed in accordance with English law and the parties irrevocably submit to the non-exclusive jurisdiction of the Courts of England and Wales in respect of any claim, dispute or difference arising out of or in connection with this letter.
(b) The obligations in this letter will terminate 18 months from the date of agreement of this letter.